智通财经APP获悉，宜明昂科-B(01541)大涨近12%，截至发稿，涨10.41%，报4.085港元，成交额342.9万港元。
消息面上，8月26日晚，宜明昂科发布2026年中期业绩，今年上上半年，公司实现收入2542.4万元，主要来自与Axion Bio订立的授权及合作协议收取的付款。公司现金储备保持充沛。截至2026年6月30日，公司现金及现金等价物、按公允价值计量的金融资产及原到期日三个月以上的定期存款合计约9.47亿元。
报告期间，公司持续快速推进药物管线的开发，在肿瘤免疫治疗及自身免疫性疾病领域均取得重要里程碑及成就。IMM01(替达派西普)、IMM0306 (阿沐瑞芙普α)及IMM2510(珀维拉芙普α)等主要临床阶段资产取得重大进展，多项关键临床试验达到重要节点。同时，公司积极拓展非肿瘤治疗领域，在自身免疫性疾病、代谢性疾病、心血管疾病及肺动脉高压方向取得显著进展，进一步释放候选药物的治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.